Breast Trials


A randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo.


An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)

Sanofi ACT16106

Phase 2 window study of two dose levels of SAR439859 (SERD) versus letrozole in newly diagnosed preoperative post-menopausal patients with ER positive, HER2 negative primary breast cancer

Seattle Genetcs SGNTUC-016 HER2CLIMB-02

Randomized, Double Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Patients with Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

Infinity IPI-546-03

A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma

Genentech WO42133

A Randomized, Multicenter, Open-Label, Two-Arm, Phase Ii, Neoadjuvant Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of Gdc-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib For Postmenopausal Women With Estrogen Receptor-Positive And Her2-Negative Untreated Early Breast Cancer

Fort Wayne North Office
(260) 484-8830
2514 E Dupont Road, Suite 100
Fort Wayne, IN 46825

Fort Wayne South Office
(260) 436-0800
7910 West Jefferson Boulevard, Suite 108
Fort Wayne, Indiana 46804

©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.